Heart Failure Society of America Updates Recommendations for Use of Cardiac Resynchronization Therapy
New recommendations explained in Journal of Cardiac Failure
New recommendations explained in Journal of Cardiac Failure
Philadelphia, PA, February 27, 2012 – Based on a review of the latest evidence, the Guidelines Committee of the Heart Failure Society of America now recommends that the use of cardiac resynchronization therapy (CRT) be expanded to a larger group of patients with mild heart failure symptoms. Recommendations for integrating new evidence into clinical practice appear in the February issue of the Journal of Cardiac Failure.
CRT devices synchronize the function of the left ventricle so that it contracts more efficiently and in a coordinated way. It does this by stimulating the part of the ventricle that is delayed in starting its contraction. This increases the efficiency of the heart and improves survival, morbidity, symptoms, and quality of life. Significant evidence supports the use of these devices, either alone or with an implantable cardioverter defibrillator (ICD), in patients with moderate or severe heart failure (graded class III or class IV according to the New York Heart Association classification system). Recent research has investigated the effect of the treatment in patients with less severe symptoms.
The committee reviewed three large randomized clinical trials of CRT in patients with mild heart failure symptoms, as well as a number of meta-analyses that evaluated the use of CRT regardless of symptom severity. “The totality of the evidence supports the use of CRT in heart failure patients with reduced left ventricular ejection function (LVEF) across the spectrum of mild to severe symptoms,” reports senior author Randall C. Starling, MD, MPH, of the Department of Cardiovascular Medicine at the Cleveland Clinic. “The evidence is most compelling among patients with an electrocardiogram QRS duration ≥ 150 ms (normal being <100 ms).”
Specifically, the Guidelines Committee determined that CRT is recommended for patients in sinus rhythm with a widened QRS interval ≥ 150 that is not due to RBBB who have reduced ejection fraction and persistent mild to moderate heart failure, despite optimal medical therapy. CRT may be considered for ambulatory class IV patients with QRS interval ≥ 150 ms and severe LV systolic dysfunction. CRT may also be considered for patients with a QRS interval of ≥ 120 to < 150 ms and severe LV systolic dysfunction, who have persistent mild to severe heart failure, despite optimal medical therapy.
The evidence supporting the QRS thresholds in these recommendations is based primarily on subgroup analyses and systematic reviews rather than on the boundaries of eligibility criteria used in the trial. “Subgroup analyses are generally limited by the potential for chance findings,” Dr. Starling notes. “However, the observations that the majority of the benefit exists in the QRS duration ≥ 150 ms subgroup has been a consistent finding across multiple clinical trials, and it has been confirmed in meta-analysis. Therefore, the Guideline Committee agreed that the totality of evidence supported the QRS duration thresholds.”
“CRT is still a relatively new technology that seemed to come out of nowhere a few years ago,” comments HFSA President, Barry Massie, MD. “However, growing evidence leaves little doubt about the value of this technology. Multiple trials have demonstrated that heart failure patients, whose hearts contract in a discordant manner, have more symptoms and poorer survival. The idea that stimulating the heart electrically to improve its efficiency could have a profound effect was greeted with some skepticism but no longer. Multiple trials have demonstrated that this intervention makes patients feel better, prevents hospitalizations, and prolongs survival in heart failure patients. I congratulate the Guideline Committee for taking on this project, reviewing a wide range of data, and making a compelling argument for increased use of this new technology that has a great deal of promise.”
Several evidence gaps must be addressed, including the ideal threshold for QRS duration, QRS morphology, lead placement, degree of myocardial scarring, and the best approach to evaluating dyssynchrony. “It is anticipated that the recommendations will evolve to focus on optimizing patient selection and identifying factors that reliably predict a favorable response to CRT, ideally based on criteria that are clinically important to our patients. We envision that this will form the substrate for guidelines to be updated by the Committee,” Dr. Starling concludes.
The article is “Indications for Cardiac Resynchronization Therapy: 2011 Update From the Heart Failure Society of American Guideline Committee,” by W.G. Stevenson, A.F. Hernandez, P.E. Carson, et al. (DOI: 10.1016/j.cardfail.2011.12.004). It appears in the Journal of Cardiac Failure, Volume 18, Issue 2 (February 2012).
# # #
Notes for editors
Full text of the article is available to credentialed journalists upon request. Contact Jane Grochowski at +1 406 542 8397 or firstname.lastname@example.org to obtain a copy. Journalists wishing to schedule interviews with the author should contact Randall C. Starling, MD, MPH, at +1 216 444 6744 or STARLIR@ccf.org.
About the authors
William G. Stevenson, MD, Department of Medicine, Division of Cardiology, Brigham and Women’s Hospital, Boston, MA
Adrian F. Hernandez, MD, Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC
Peter E. Carson, MD, Georgetown University and Washington DC Veterans Affairs Medical Center, Washington, DC
James C. Fang, Harrington-McLaughlin Heart and Vascular Institute, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH
Stuart D. Katz, MD, Leon H. Charney Division of Cardiology, New York University School of Medicine, New York, NY
John A. Spertus, MD, MPH, Mid-America Heart Institute of St. Luke’s Hospital and University of Missouri – Kansas City, Kansas City, MO
Nancy K. Sweitzer, MD, PhD, Department of Medicine, University of Wisconsin, Madison, WI
W.H. Wilson Tang, MD, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
Nancy M. Albert, RN, PhD, CNS, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH
Javed Butler, MD, Department of Medicine, Division of Cardiology, Emory University, Atlanta, GA
Cheryl A. Westlake Canary, RN, PhD, School of Nursing, Azusa Pacific University, Azusa, CA,
Sean P. Collins, MD, MSc, Department of Emergency Medicine, Vanderbilt University, Nashville, TN
Monica Colvin-Adams, MD, Cardiovascular Division, University of Minnesota, Minneapolis, MN
Justin A. Ezekowitz, MBBCh, Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada
Michael M. Givertz, MD, Department of Medicine, Division of Cardiology, Brigham and Women’s Hospital, Boston, MA
Ray E. Hershberger, MD, Department of Medicine, Division of Cardiology, University of Miami, Miami, FL
Joseph G. Rogers, MD, Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC
John R. Teerlink, MD, Department of Medicine, University of California, San Francisco, CA
Mary N. Walsh, MD, The Care Group, Indianapolis, IN
Wendy Gattis Stough, PharmD, Department of Clinical Research, Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC
Randall C. Starling, MD, MPH, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
About the Journal of Cardiac Failure
Journal of Cardiac Failure publishes original, peer-reviewed communications of scientific excellence and review articles on clinical research, basic human studies, animal studies, and bench research with potential clinical applications to heart failure -pathogenesis, etiology, epidemiology, pathophysiological mechanisms, assessment, prevention, and treatment.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 33,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Health Sciences Journals, Elsevier
+1 406 542 8397